PMID- 33378562
OWN - NLM
STAT- MEDLINE
DCOM- 20210831
LR  - 20220402
IS  - 1365-2893 (Electronic)
IS  - 1352-0504 (Print)
IS  - 1352-0504 (Linking)
VI  - 28
IP  - 4
DP  - 2021 Apr
TI  - Proton pump inhibitor usage reduces sustained viral response rates for veterans 
      with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a 
      multicentre VA cohort.
PG  - 630-636
LID - 10.1111/jvh.13462 [doi]
AB  - Previous studies have reported an association of proton pump inhibitor (PPI) use 
      and decreased sustained viral response rate (SVR) in patients taking 
      ledipasvir/sofosbuvir (LDV/SOF). The relationship between PPI usage and SVR is 
      less clear in patients with HIV/HCV coinfection, where concomitant 
      antiretrovirals may result in more complex drug interactions. This retrospective 
      study evaluates the effects of acid suppression medications (PPI or H(2) 
      -receptor antagonist [H(2) B]) use and SVR rates in patients with HIV/HCV or HCV 
      and taking LDV/SOF in a large multicentre veteran cohort. Patients in the 
      Veterans Affairs Health Care System who received LDV/SOF +/- ribavirin from 
      10/10/2014 to 12/31/2015 were included. The odds ratios (OR) of PPI or H(2) B use 
      for SVR were adjusted for clinical factors and with inverse probability of 
      treatment weighting for non-random treatment selection for acid suppression 
      medication use. There were 9703 veterans included in our final analysis. After 
      adjustment of other clinical factors, PPI use is associated with a lower SVR in 
      the overall cohort (95.0% vs. 96.1%, OR: 0.86, 95% CI: 0.74-0.99, p = .03, number 
      needed to harm 90.9) and HIV/HCV coinfection subgroup (93.4% vs. 96.9%, OR: 0.47, 
      95% CI: 0.26-0.85, p = .01, number needed to harm 28.6). This present study 
      reveals PPI use is associated with reduced SVR after LDV/SOF treatment, with a 
      more significant impact in the subgroup of patients with HIV/HCV coinfection. 
      Precautions need to be taken when using PPI and LDV/SOF in this group of 
      patients.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Lee, Tzu-Hao
AU  - Lee TH
AUID- ORCID: 0000-0002-2478-3447
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, NC, USA.
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Chan, Austin
AU  - Chan A
AD  - Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA.
FAU - Bryan, William
AU  - Bryan W
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Park, Lawrence
AU  - Park L
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
AD  - Division of infectious diseases, Department of Medicine, Duke University School 
      of Medicine, Durham, NC, USA.
FAU - Hashem, Mohamed
AU  - Hashem M
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Townsend, Mary
AU  - Townsend M
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Moylan, Cynthia
AU  - Moylan C
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, NC, USA.
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Britt, Rachel
AU  - Britt R
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Choi, Steve
AU  - Choi S
AD  - Division of Gastroenterology, Department of Medicine, Duke University School of 
      Medicine, Durham, NC, USA.
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
FAU - Naggie, Susanna
AU  - Naggie S
AD  - Durham Veterans Affairs Health Care System, Durham, NC, USA.
AD  - Division of infectious diseases, Department of Medicine, Duke University School 
      of Medicine, Durham, NC, USA.
LA  - eng
GR  - P30 AI064518/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20210128
PL  - England
TA  - J Viral Hepat
JT  - Journal of viral hepatitis
JID - 9435672
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Fluorenes)
RN  - 0 (Proton Pump Inhibitors)
RN  - 013TE6E4WV (ledipasvir)
RN  - WJ6CA3ZU8B (Sofosbuvir)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Benzimidazoles
MH  - *Coinfection/drug therapy
MH  - Drug Therapy, Combination
MH  - Fluorenes/therapeutic use
MH  - *HIV Infections/complications/drug therapy
MH  - Hepacivirus
MH  - *Hepatitis C/complications/drug therapy
MH  - Humans
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Retrospective Studies
MH  - Sofosbuvir/therapeutic use
MH  - Treatment Outcome
MH  - *Veterans
PMC - PMC8054484
MID - NIHMS1683627
OTO - NOTNLM
OT  - HCV
OT  - HIV
OT  - ledipasvir
OT  - proton pump inhibitor
OT  - sofosbuvir
COIS- CONFLIC T OF INTERESTS A.C. was funded in part by T32 grant from NIH during this 
      study. S.N. reports support to her institution for clinical research protocols 
      from Gilead Sciences, AbbVie, Janssen, Tacere.
EDAT- 2020/12/31 06:00
MHDA- 2021/09/01 06:00
PMCR- 2022/04/01
CRDT- 2020/12/30 17:14
PHST- 2020/04/30 00:00 [received]
PHST- 2020/10/04 00:00 [revised]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/09/01 06:00 [medline]
PHST- 2020/12/30 17:14 [entrez]
PHST- 2022/04/01 00:00 [pmc-release]
AID - 10.1111/jvh.13462 [doi]
PST - ppublish
SO  - J Viral Hepat. 2021 Apr;28(4):630-636. doi: 10.1111/jvh.13462. Epub 2021 Jan 28.